<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
AMENDMENT NO. 1
ON
FORM 10-Q/A
---------
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 1997
-------------
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from_______________to_______________
Commission file number 0-14680
-------
GENZYME CORPORATION
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Massachusetts 06-1047163
- --------------------------------------------------------------------------------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
One Kendall Square, Cambridge, Massachusetts 02139
- --------------------------------------------------------------------------------
(Address of principal executive offices) (zip code)
(617) 252-7500
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
--- ---
The number of shares outstanding of each of the issuer's series of common stock
as of July 31, 1997:
<TABLE>
<CAPTION>
Series Outstanding at July 31, 1997
------ ----------------------------
<S> <C>
Genzyme General Division Common Stock
("GGD Stock") 76,730,738
Genzyme Tissue Repair Division Common Stock
("GTR Stock") 15,715,885
Genzyme Molecular Oncology Division Common Stock
("GMO Stock") 3,928,571
</TABLE>
<PAGE> 2
GENZYME CORPORATION AND SUBSIDIARIES
FORM 10-Q/A, JUNE 30, 1997
This Amendment No. 1 on Form 10-Q/A for the fiscal quarter ended June 30, 1997
has been filed to amend Part II, Item 4 "Submission of Matters to a Vote of
Security Holders," in which the voting on the proposal described in subsection
II a. thereof was previously erroneously reported as the voting on the proposal
described in subsection II b. thereof, and vice versa. This Amendment No. 1 on
Form 10-Q/A contains the corrected report on the voting on the proposals
described under subsections II a. and II b. of Item 4.
2
<PAGE> 3
GENZYME CORPORATION AND SUBSIDIARIES
FORM 10-Q/A, JUNE 30, 1997
PART II. OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
I. The Company held an annual meeting of its stockholders on May 29,
1997. The following represents the results of the voting on proposals
submitted to a vote of stockholders at such meeting:
a. Proposal to elect two directors for a term of office expiring
in 2000:
<TABLE>
<CAPTION>
Nominee
-------
Henri A. Termeer
Number of Number of Number of Votes Number of
Votes For Votes Withheld Abstaining Broker Non-Votes
---------- -------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 58,318,091 520,720 0 0
GTR* 3,810,615 37,406 0 0
---------- ------- -- --
Total 62,128,706 558,126 0 0
</TABLE>
<TABLE>
<CAPTION>
Nominee
-------
Henry R. Lewis
Number of Number of Number of Votes Number of
Votes For Votes Withheld Abstaining Broker Non-Votes
---------- -------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 58,318,872 519,939 0 0
GTR* 3,809,835 38,186 0 0
---------- ------- -- --
Total 62,128,707 558,125 0 0
</TABLE>
b. Proposal to amend the Company's 1990 Employee Stock Purchase
Plan (the "ESPP") to increase the number of shares of GGD stock
available shares for issuance under such plan from 1,500,000 to
2,000,000 shares.
<TABLE>
<CAPTION>
Number of Number of Votes Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 46,595,790 11,943,850 299,171 0
GTR* 3,229,593 601,333 17,095 0
---------- ---------- ------- --
Total 49,825,383 12,545,183 316,266 0
</TABLE>
c. Proposal to amend the ESPP to increase the number of shares
of GTR stock available for issuance under such plan from
600,000 to 1,100,000 shares.
<TABLE>
<CAPTION>
Number of Number of Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 46,263,732 12,271,324 303,755 0
GTR* 3,100,525 729,356 18,140 0
---------- ---------- ------- --
Total 49,364,257 13,000,680 321,895 0
</TABLE>
d. Proposal to amend the Company's 1988 Director Stock Option
Plan (the "Director Plan") to increase the number of shares of
GGD stock available for issuance under such plan from 200,000
to 233,600 shares.
<TABLE>
<CAPTION>
Number of Number of Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 51,891,846 6,658,603 288,362 0
GTR* 3,246,176 580,342 21,503 0
---------- --------- ------- --
Total 55,138,022 7,238,945 309,865 0
</TABLE>
3
<PAGE> 4
GENZYME CORPORATION AND SUBSIDIARIES
FORM 10-Q/A, JUNE 30, 1997
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS (CONTINUED)
e. Proposal to amend the Director Plan to increase the number of
shares of GTR Stock available for issuance under such plan from
70,000 to 100,000 shares.
<TABLE>
<CAPTION>
Number of Number of Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 51,894,710 6,653,286 290,815 0
GTR* 3,220,607 605,908 21,506 0
---------- --------- ------- --
Total 55,115,317 7,259,194 312,321 0
</TABLE>
----------
* Represents the actual number of shares of GTR Stock voted
multiplied by .33.
II. The Company held a special meeting of its stockholders on June
12, 1997. The following represents the results of the voting on
proposals submitted to a vote of stockholders at such meeting:
a. Proposal to approve the Merger Agreement between Genzyme and
PharmaGenics which provides for the merger of PharmaGenics with
and into Genzyme and the issuance of shares of GMO Stock in
connection therewith.
<TABLE>
<CAPTION>
Number of Number of Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 39,859,153 881,042 220,400
GTR* 2,264,547 59,707 28,361
---------- ------- -------
Total 42,123,700 940,749 248,761 6,953,718
</TABLE>
b. Proposal to amend and restate the articles of
organization of Genzyme to redesignate Genzyme's existing
classes of common stock as separate series of a single class
of common stock and to authorize 150,000,000 shares of
undesignated common stock that may be issued from time to
time by the Genzyme Board in one or more series.
<TABLE>
<CAPTION>
Number of Number of Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 45,764,726 1,756,657 249,597 0
GTR* 2,347,090 114,015 34,843 0
---------- --------- ------- --
Total 48,111,816 1,870,672 284,440 0
</TABLE>
c. Proposal to amend the 1990 Equity Incentive Plan to
authorize the granting of awards under such plan relating to
GMO stock.
<TABLE>
<CAPTION>
Number of Number of Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 27,675,435 14,936,206 1,750,379
GTR* 1,662,846 794,153 38,948
---------- ---------- ---------
Total 29,338,281 15,730,359 1,789,327 3,408,961
</TABLE>
d. Proposal to amend the Director Plan to authorize the granting
of options to purchase GMO stock under such plan.
<TABLE>
<CAPTION>
Number of Number of Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 30,770,739 13,280,794 310,487
GTR* 1,778,214 677,711 40,022
---------- ---------- -------
Total 32,548,953 13,958,505 350,509 3,408,961
</TABLE>
4
<PAGE> 5
GENZYME CORPORATION AND SUBSIDIARIES
FORM 10-Q/A, JUNE 30, 1997
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS (CONTINUED)
e. Proposal to amend the ESPP to authorize the granting of stock
purchase rights under such plan relating to GMO stock.
<TABLE>
<CAPTION>
Number of Number of Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 32,529,086 11,555,952 276,982
GTR* 1,912,640 544,172 39,135
---------- ---------- -------
Total 34,441,726 12,100,124 316,117 3,408,961
</TABLE>
f. Proposal to amend the Directors' Deferred Compensation
Plan to authorize the distribution of shares of GMO stock
credited to stock accounts under such plan.
<TABLE>
<CAPTION>
Number of Number of Number of Votes Number of
Votes for Votes Against Abstaining Broker Non-Votes
---------- ------------- --------------- ----------------
<S> <C> <C> <C> <C>
GGD 42,095,920 1,941,213 320,887
GTR* 2,327,073 127,984 40,890
---------- --------- -------
Total 44,422,993 2,069,197 361,777 3,412,961
</TABLE>
----------
* Represents the actual number of shares of GTR Stock voted
multiplied by .33.
5
<PAGE> 6
GENZYME CORPORATION AND SUBSIDIARIES
FORM 10-Q/A, JUNE 30, 1997
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
GENZYME CORPORATION
DATE: September 17, 1997 By: /s/ David J. McLachlan
----------------------------------------
David J. McLachlan
Duly Authorized Officer and
Executive Vice President, Finance;
Chief Financial Officer
6
